Key result
Alteplase therapy for acute myocardial infarction markedly increased plasma levels of PAI-1 antigen and activity, while FPA levels increased under alteplase alone and normalized with heparin.
Why the study?
Does alteplase therapy alter plasma levels of PAI-1, beta TG, and FPA in patients with acute myocardial infarction?
Cohort (n=30)
Does alteplase therapy alter plasma levels of PAI-1, beta TG, and FPA in patients with acute myocardial infarction?
Alteplase therapy for acute myocardial infarction induces a marked post-treatment increase in PAI-1 levels, while concomitant heparin is essential to control fibrin generation.
Answers are grounded in this paper and cite their sources.
Emphasizes heparin co-therapy necessity with alteplase in AMI; leaves open PAI-1 effects on reperfusion outcomes.
Plasma levels of plasminogen activator inhibitor type-1 (PAI-1), beta-thromboglobulin (beta TG), and fibrinopeptide A (FPA) were followed over 24 hours in 30 patients treated with alteplase for acute myocardial infarction. Samples were taken at baseline (T Oh), after 90 minutes (under alteplase, no heparin, T 1.5h), after 120 minutes (under alteplase and heparin, T 2h), 30 minutes after thrombolytic therapy (T 3.5h), as well as 12 hours (T 12h) and 24 hours (T 24h) after baseline. PAI-1 antigen levels (55 +/- 9 ng/mL at T Oh, mean +/- SEM) decreased to 35 +/- 5 (T 1.5h) and 40 +/- 6 (T 2h) ng/mL under alteplase, before increasing to 84 +/- 22 (T 3.5h), 130 +/- 30 (T 12h), and 64 +/- 7 (T 24h) ng/mL after therapy, P less than .001. A high baseline PAI-1 activity (18 +/- 3 ng/mL) decreased to 2.0 +/- 0.4 (T 1.5h) and 1.7 +/- 0.2 (T 2h) under alteplase and increased to 32 +/- 5 (T 12h) and 19 +/- 3 (T 24h) ng/mL after therapy (P less than .0001). beta TG levels (339 +/- 105 ng/mL at T Oh) decreased to 203 +/- 48 (T 2h), 154 +/- 51 (T 3.5h), 187 +/- 40 (T 12h), and 142 +/- 32 (T 24h) ng/mL under heparin (P less than .01). FPA levels (34 +/- 9 ng/mL at T Oh) increased to 85 +/- 15 ng/mL under alteplase alone (T 1.5h) and normalized under heparin (11 +/- 4, 6 +/- 2, 4 +/- 2, and 3 +/- 1 ng/mL at T 2h, T 3.5h, T 12h, and T 24h, respectively). A high level of FPA at T 3.5h correlated with reocclusion (33 +/- 12 ng/mL, n = 4 v 2.9 +/- 0.5 ng/mL, n = 21, P less than .005). We conclude that plasma levels of PAI-1 antigen as well as activity markedly increase after alteplase therapy of acute myocardial infarction. The high activity of PAI-1 and decreasing beta TG levels suggest that platelets do not contribute significantly to this phenomenon. The marked increase of FPA levels under recombinant tissue-type plasminogen activator alone and its normalization under heparin emphasize the important role of concomitant anticoagulation in controlling further intravasal fibrin generation under alteplase.
No takes yet. Share an insight, caveat, or question.
Rapold et al. (1991) conducted a cohort in acute myocardial infarction (n=30). Alteplase vs. Baseline was evaluated on Plasma levels of PAI-1 antigen (p=<.001). Alteplase therapy for acute myocardial infarction markedly increased plasma levels of PAI-1 antigen and activity, while FPA levels increased under alteplase alone and normalized with heparin.
Synapse has enriched 10 related papers. Consider them for comparative context: